A detailed history of Algert Global LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Algert Global LLC holds 516,209 shares of BCRX stock, worth $3.91 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
516,209
Previous 353,133 46.18%
Holding current value
$3.91 Million
Previous $2.18 Million 79.79%
% of portfolio
0.11%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.41 - $8.69 $1.05 Million - $1.42 Million
163,076 Added 46.18%
516,209 $3.92 Million
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $228,434 - $375,561
55,311 Added 18.57%
353,133 $2.18 Million
Q1 2024

May 14, 2024

SELL
$4.89 - $7.65 $190,431 - $297,913
-38,943 Reduced 11.56%
297,822 $1.51 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $645,756 - $877,865
129,670 Added 62.61%
336,765 $2.02 Million
Q3 2023

Nov 13, 2023

SELL
$6.71 - $7.92 $566,733 - $668,931
-84,461 Reduced 28.97%
207,095 $1.47 Million
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $212,767 - $269,321
30,570 Added 11.71%
291,556 $2.05 Million
Q1 2023

May 12, 2023

BUY
$7.94 - $11.84 $818,153 - $1.22 Million
103,042 Added 65.24%
260,986 $2.18 Million
Q4 2022

Feb 13, 2023

BUY
$10.5 - $14.2 $638,578 - $863,601
60,817 Added 62.62%
157,944 $1.81 Million
Q3 2022

Nov 15, 2022

BUY
$10.79 - $14.81 $206,509 - $283,448
19,139 Added 24.54%
97,127 $1.22 Million
Q2 2022

Aug 15, 2022

BUY
$7.89 - $17.88 $77,905 - $176,547
9,874 Added 14.5%
77,988 $825,000
Q1 2022

May 16, 2022

BUY
$11.56 - $19.76 $555,550 - $949,626
48,058 Added 239.62%
68,114 $1.11 Million
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $284,995 - $353,988
20,056 New
20,056 $288,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.